KDIGO Commentaries, organized by topic:
CARDIO-KIDNEY-METABOLIC (CKM) SYNDROME
DIABETES
IgAN
KDIGO
Commentaries on KDIGO Guidelines and Publications, organized by topic:
ACUTE KIDNEY INJURY (AKI)
- (2012) – Canadian Society of Nephrology Commentary on 2012 KDIGO AKI Guideline
- (2012) – European Renal Best Practice Position statement on the KDIGO Clinical Practice Guidelines on Acute Kidney Injury Part 2
- (2012) – KDOQI US Commentary on the 2012 KDIGO Clinical Practice Guideline for Acute Kidney Injury
ANCA VASCULITIS
ANEMIA
- (2026) – KDOQI US Commentary on the KDIGO 2026 Anemia in CKD Guideline
- (2012) – Canadian Society of Nephrology Commentary on the 2012 KDIGO Clinical Practice Guideline for Anemia in CKD
- (2012) – KDOQI US Commentary on the 2012 KDIGO Clinical Practice Guideline for Anemia in CKD
- (2012) – KHA-CARI International treatment guidelines for anaemia in chronic kidney disease — what has changed?
AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE (ADPKD)
BLOOD PRESSURE IN CKD
- (2022) – KDOQI US Commentary on the 2021 KDIGO Clinical Practice Guideline for Management of Blood Pressure in CKD
- (2021) – Annals of Internal Medicine Management of Blood Pressure in Patients with Chronic Kidney Disease Not Receiving Dialysis: Synopsis of the 2021 KDIGO Clinical Practice Guideline
- (2021) – ASN Kidney News – KDIGO Blood Pressure Guideline Emphasizes Standardized Measurement, Tight Control
- (2014) – Canadian Society of Nephrology Commentary on the 2012 KDIGO Clinical Practice Guideline for the Management of Blood Pressure in CKD
- (2013) – European Renal Best Practice Position statement on the KDIGO Clinical Practice Guideline for the Management of Blood Pressure in Non-dialysis-dependent Chronic Kidney Disease: an endorsement with some caveats for real-life application
- (2013) – KDOQI US Commentary on the 2012 KDIGO Clinical Practice Guideline for Management of Blood Pressure in CKD
CHRONIC KIDNEY DISEASE (CKD)
- (2025) – KDOQI US Commentary on the KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of CKD
- (2015) – Canadian Society of Nephrology Commentary on the KDIGO Clinical Practice Guideline for CKD Evaluation and Management
- (2013) – KDOQI US Commentary on the 2012 KDIGO Clinical Practice Guideline for the Evaluation and Management of CKD
CKD MINERAL AND BONE DISORDER (CKD-MBD)
- (2018) – United Kingdom Renal Association Commentary on the 2017 KDIGO Guideline on the Diagnosis, Evaluation, Prevention and Treatment of CKD-MBD
- (2017) – KDOQI: US Commentary on the 2017 KDIGO Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease–Mineral and Bone Disorder (CKD-MBD)
- (2017) – Nature Reviews of Nephrology: KDIGO 2017 CKD–MBD guideline update: evolution in the face of uncertainty
- (2010) – Canadian Society of Nephrology Commentary on the 2009 KDIGO Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of CKD–Mineral and Bone Disorder (CKD-MBD)
- (2010) – European Renal Best Practice: Endorsement of the 2009 KDIGO Chronic Kidney Disease–Mineral and Bone Disorder (CKD-MBD) Guidelines
- (2o10) – KDOQI: US Commentary on the 2009 KDIGO Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of CKD–Mineral and Bone Disorder (CKD-MBD)
- (2010) – United Kingdom Renal Association: How do the 2009 KDIGO Clinical Practice Guidelines on CKD – MBD apply to the UK?
DIABETES IN CKD
- (2026) – CARI Commentary on KDIGO 2022 Diabetes in CKD Guideline
- (2025) – GLP-1 receptor agonists and other incretin mimetics for diabetes and chronic kidney disease—a KDIGO commentary
- (2020) – Annals of Internal Medicine: Diabetes Management in Chronic Kidney Disease: Synopsis of the 2020 KDIGO Clinical Practice Guideline
- (2020) – Guidelines UK: Clinical practice guideline for diabetes management in chronic kidney disease
- (2020) – KDOQI US Commentary on the KDIGO 2020 Clinical Practice Guideline for Diabetes Management in CKD
GLOMERULAR DISEASES
- (2021) – KDOQI US Commentary on the 2021 KDIGO Clinical Practice Guideline for the Management of Glomerular Diseases
- (2012) – Canadian Society of Nephrology Commentary on the 2012 KDIGO Clinical Practice Guideline for Glomerulonephritis: Management of Nephrotic Syndrome in Children
- (2012) – Canadian Society of Nephrology Commentary on the 2012 KDIGO Clinical Practice Guideline for Glomerulonephritis: Management of Glomerulonephritis in Adults
- (2012) – KDOQI: US Commentary on the 2012 KDIGO Clinical Practice Guideline for Glomerulonephritis
HEPATITIS C
- (2018) – KDOQI: US Commentary on the 2018 KDIGO Clinical Practice Guideline for the Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C
- (2018) – KDOQI: KDIGO Response to the KDOQI US Commentary on the 2018 Hepatitis C Guideline
IgA NEPHROPATHY (IgAN) and IgA Vasculitis (IgAV)
- (2026) – KDOQI: US Commentary on the KDIGO 2025 IgAN/IgAV Guideline
- (2025) – Treatment of Patients with IgA Nephropathy: A Call for a New Paradigm
LIPIDS
- (2015) – KDOQI: US Commentary on the 2013 KDIGO Clinical Practice Guideline for Lipid Management in CKD
- (2014) – KHA-CARI: Commentary on the KDIGO 2013 Clinical Practice Guideline for Lipid Management in Chronic Kidney Disease
LIVING KIDNEY DONOR
NOMENCLATURE
- (2020) – Nephrology Nursing Journal: IMPROVING COMMUNICATION: A NEW STANDARDIZED NOMENCLATURE FOR KIDNEY FUNCTION AND DISEASE
- (2020) – Editorial Commentary: KDIGO nomenclature glossary for Pediatric Nephrology
TRANSPLANT RECIPIENT
- (2012) – European Renal Best Practice: Endorsement of the KDIGO guidelines on kidney transplantation
- (2010) – Canadian Society of Transplantation & Canadian Society of Nephrology: Commentary on the 2009 KDIGO Clinical Practice Guideline for the Care of Kidney Transplant Recipients
- (2010) – KDOQI: US Commentary on the 2009 KDIGO Clinical Practice Guideline for the Care of Kidney Transplant Recipients
